These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A preliminary study of the potential role of FGF-23 in coronary calcification in patients with suspected coronary artery disease.
    Author: Masai H, Joki N, Sugi K, Moroi M.
    Journal: Atherosclerosis; 2013 Jan; 226(1):228-33. PubMed ID: 23137826.
    Abstract:
    OBJECTIVE: The association of fibroblast growth factor 23 (FGF-23) with vascular disease in patients with preserved renal function is not well understood. The purpose of this study was to investigate the relationship of serum FGF-23 with coronary calcification in patients without chronic kidney disease and diabetes mellitus (DM). METHODS: A cross-sectional study was performed in 148 consecutive patients with suspected coronary artery disease who underwent 64-slice computed tomography coronary angiography for diagnosis of coronary artery disease. Patients with eGFR <60 mL/min/1.73 m(2), proteinuria, or DM were excluded. Associations of coronary calcification (evaluated by Agatston score) were examined with classical risk factors and with inflammatory markers, adipocytokines and FGF-23. RESULTS: The median creatinine, eGFR and FGF-23 levels were 0.7 mg/dL, 74.6 mL/min/1.73 m(2), and 26 pg/mL respectively. The strongest association was found between age and Agatston score (r = 0.367, p < 0.001) in univariate logistic regression analysis. No atherogenic risk factors, including inflammatory markers and adipocytokine levels, were associated with Agatston score. Among calcium/phosphate metabolism markers, FGF-23 showed a weak but significant correlation with Agatston score (r = 0.169, p = 0.039). In multivariate linear regression analysis, age and FGF-23 (r = 0.188, p = 0.016) were independently associated with the Agatston score. CONCLUSION: Serum FGF-23 levels were associated with coronary calcification independently of classical risk factors and of adipocytokines and inflammatory markers in patients with preserved renal function. FGF-23 may also have a direct effect on progression of coronary calcification and further studies are required to examine this issue.
    [Abstract] [Full Text] [Related] [New Search]